Lage, Daniela PagliaraRibeiro, Patrícia Aparecida FernandesDias, Daniel SilvaMendonça, Débora Vasconcelos CostaRamos, Fernanda FonsecaCarvalho, Lívia MendesSteiner, Bethina TrevisolTavares, Grasiele de Sousa VieiraMartins, Vivian TamiettiMachado, Amanda SanchezSilva, João Augusto Oliveira daSantos, Thaís Teodoro de OliveiraFreitas, Camila Simões deOliveira, Jamil Silvano deRoatt, Bruno MendesÁvila, Ricardo Andrez Machado deHumbert, Maria VictoriaChristodoulides, MyronCoelho, Eduardo Antônio Ferraz2021-09-302021-09-302020LAGE, D. P. et al. Liposomal formulation of ChimeraT, a multiple T-cell epitope-containing recombinant protein, is a candidate vaccine for human Visceral Leishmaniasis. Vaccines, v. 8, n. 2, artigo 289, jun. 2020. Disponível em: <https://www.mdpi.com/2076-393X/8/2/289>. Acesso em: 10 jun. 2021.2076-393Xhttp://www.repositorio.ufop.br/jspui/handle/123456789/13831Background: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation. Methods: BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo. Results: Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels. Conclusions: Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL.en-USabertoSaponinTh1-type immunityArtigo publicado em periodicoThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Fonte: o PDF do artigo.https://doi.org/10.3390/vaccines8020289